Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2.
Mishra
S
S
Pertz
V
V
Zhang
B
B
Kaur
P
P
Shimada
H
H
Groffen
J
J
Kazimierczuk
Z
Z
Pinna
L A
LA
Heisterkamp
N
N
D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D047390:Casein Kinase II / Q000037:antagonists & inhibitors*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D016044:Fusion Proteins, bcr-abl; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D051379:Mice
C492322:2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole; C475924:4,5,6,7-tetrabromobenzimidazole; D001562:Benzimidazoles; D016044:Fusion Proteins, bcr-abl; D047390:Casein Kinase II